Pharmaceuticals
BiomX Inc.: A Biotech Pioneer with Pentagon Backing and Promising Phage Therapy
BiomX Inc. (NYSE: PHGE), a biotech company with a market cap of $13 million, has secured $40 million in non-dilutive funding from the U.S. Defense Health Agency, highlighting its potential in addressing antibiotic-resistant infections with phage therapy.
ABVC BioPharma CEO Recognized Among Influential Indian-Origin CEOs in Global Biotech
Dr. Uttam Patil, CEO of ABVC BioPharma, is highlighted for his leadership in advancing a novel botanical antidepressant, ABV-1504, which could revolutionize treatment for Major Depressive Disorder by eliminating suicidal ideation side effects.
Gilead Sciences and Unite for HER Launch Program to Support Metastatic Breast Cancer Patients
Gilead Sciences partners with Unite for HER to offer free integrative care to Black, Hispanic, and underserved metastatic breast cancer patients in the U.S., enhancing treatment adherence and quality of life.
InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment
InMed Pharmaceuticals Inc. announces positive preclinical results for INM-901, showing potential in reducing neuroinflammation associated with Alzheimer's disease, independent of amyloid beta or tau pathology.
Creative Biolabs Advances Liposome Technology for Enhanced Drug Delivery
Creative Biolabs is pioneering liposome technology to improve drug delivery systems, offering innovative solutions for pharmaceutical industries and beyond.
Nutriband Inc. (NASDAQ: NTRB) Sees Price Target Increase to $15 After AVERSA Fentanyl Manufacturing Achievement
Nutriband Inc.'s price target was raised to $15 following the successful commercial manufacturing and scale-up of its AVERSA Fentanyl abuse-deterrent transdermal patch, marking a significant step towards clinical trials and potential market entry.
Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents
Lexaria Bioscience Corp. has reached a significant milestone with 50 patents granted worldwide, including new patents for epilepsy treatment and sublingual nicotine delivery, marking a pivotal moment in the company's strategy to expand its drug delivery platform.
Nutriband Inc. Secures U.S. Patent for AVERSA(TM) Technology, Aiming to Curb Drug Abuse
Nutriband Inc.'s new U.S. patent for its AVERSA(TM) technology marks a significant step forward in preventing the misuse and abuse of transdermal drugs, addressing a critical aspect of the ongoing opioid crisis.
Nuvectis Pharma Attracts Significant Insider Investment Amid Promising Oncology Pipeline
Nuvectis Pharma's strategic insider buying and advanced oncology pipeline position it as a potential breakout biotech in 2025.
Annovis Bio Inc. Secures 18-Month NYSE Compliance Extension
Annovis Bio Inc. (NYSE: ANVS) has been granted an 18-month period by the NYSE to meet listing requirements, ensuring continued trading of its shares while it advances therapies for neurodegenerative diseases.
Telomir Pharmaceuticals Reports Preclinical Success for Telomir-1 in Progeria Cell Lines
Telomir Pharmaceuticals' preclinical data shows Telomir-1's potential in preventing cellular aging in progeria cell lines, marking a significant advancement in treating Hutchinson-Gilford Progeria Syndrome (HGPS).
Soligenix's SGX302 Shows Promise in Psoriasis Treatment
Soligenix Inc.'s SGX302, a novel therapy for psoriasis, has demonstrated effectiveness and safety in Phase 2a trials, offering hope to millions affected by this autoimmune disorder.
Nutriband Inc. Advances Aversa Fentanyl to Commercial Manufacturing Scale with Kindeva
Nutriband Inc. and Kindeva have successfully scaled up the commercial manufacturing process for Aversa Fentanyl, an abuse-deterrent opioid patch, marking a significant step towards addressing the opioid crisis with innovative technology.
NanoViricides' NV-387 Emerges as a Promising Broad-Spectrum Antiviral Against COVID-19 and Bird Flu
NanoViricides, Inc. highlights NV-387, its broad-spectrum antiviral candidate, as a potential game-changer in combating emerging COVID-19 variants and Bird Flu strains, showcasing its superior performance in animal models and readiness for cGMP manufacturing.
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. with Focus on ADHD Treatment Innovation
Stonegate Capital Partners has begun coverage on Cingulate Inc., highlighting the company's progress with CTx-1301, a potential breakthrough in ADHD treatment, targeting a significant market opportunity.
Jupiter Neurosciences' Dual Strategy Paves Way for Biotech Innovation and Revenue Stability
Jupiter Neurosciences Inc. combines clinical drug development with a direct-to-consumer product line to address neuroinflammation and rare diseases, ensuring both long-term impact and short-term revenue amidst industry challenges.
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment
Tonix Pharmaceuticals Holding Corp. has unveiled positive Phase 3 trial data for TNX-102 SL, a potential breakthrough in fibromyalgia treatment, showcasing significant pain reduction and improved sleep quality, marking a significant advancement in pain management therapies.
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter
Tonix Pharmaceuticals Holding Corp. has appointed Jim Hunter to its Board of Directors, leveraging his commercial expertise as the company prepares for the potential launch of TNX-102 SL for fibromyalgia, marking a significant step in its growth and product development strategy.
Nutriband Inc. Reports Significant Revenue Growth and Advances in AVERSA Fentanyl Development
Nutriband Inc. showcases a 63% year-over-year revenue increase in Q1 2025 and progresses in developing AVERSA Fentanyl, aiming to introduce the first abuse-deterrent opioid patch globally.
Scinai Immunotherapeutics Ltd. Showcases Strategic Milestones and Funding Ahead of BIO 2025
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) prepares for the BIO International Convention 2025, highlighting its CDMO business growth and nanobody pipeline progress, alongside securing $1.38 million in funding to support its operations without additional dilution.
Telomir Pharmaceuticals Reports Significant Preclinical Breakthrough with Telomir-1 in Wilson’s Disease Model
Telomir Pharmaceuticals' preclinical data reveals Telomir-1's potential to reverse symptoms of Wilson’s disease, a rare copper accumulation disorder, marking a significant step towards human trials and offering hope for patients.
Lifordi Immunotherapeutics Unveils Promising Preclinical Data for LFD-200 at EULAR 2025
Lifordi Immunotherapeutics has presented preclinical data on LFD-200, a novel antibody-drug conjugate targeting autoimmune and inflammatory diseases, showing efficacy without systemic toxicity, marking a potential breakthrough in treatment options.
Pacylex Pharmaceuticals Showcases Promising NMT Inhibitors at BIO Annual Meeting
Pacylex Pharmaceuticals Inc. highlights its innovative N-myristoyltransferase inhibitors (NMTis) at the BIO International Convention, showcasing potential breakthroughs in cancer treatment through oral zelenirstat and ADC payloads.
Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention
Tonix Pharmaceuticals Holding Corp. is set to present at the 2025 BIO International Convention, highlighting its advancements in pain management and public health solutions, including a potential new treatment for fibromyalgia.
Medicus Pharma Ltd. (NASDAQ: MDCX) Strategically Positions Itself in the Rapidly Growing $5 Trillion Biotech Market
Medicus Pharma Ltd. is leveraging the aging global population and technological advancements in biopharma to address chronic diseases, positioning itself for significant growth in the $5 trillion biotech market by 2034.
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events
Oragenics Inc. (NYSE American: OGEN) is set to present its intranasal neurosteroid candidate for concussion treatment, ONP-002, at two significant 2025 events, highlighting its potential impact on neurology and pharmaceutical sectors.
Tevard Biosciences Appoints Dr. Elisabeth Gardiner as Chief Scientific Officer to Advance tRNA-Based Therapies
Tevard Biosciences has appointed Dr. Elisabeth Gardiner as its new Chief Scientific Officer, marking a significant step in advancing its tRNA-based therapies for genetic diseases, with implications for treating conditions like Duchenne Muscular Dystrophy and TTN-related dilated cardiomyopathy.
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology
Nutriband Inc. has been granted a U.S. patent for its Aversa(TM) technology, marking a significant step forward in the fight against drug abuse and misuse with its abuse-deterrent transdermal products.
Soligenix's HyBryte(TM) Offers New Hope for CTCL Patients with FDA Orphan Drug Designation
Soligenix Inc. advances in the treatment of Cutaneous T-cell lymphoma (CTCL) with HyBryte(TM), a photodynamic therapy showing promise in clinical trials and receiving Orphan Drug Designation, addressing a critical need for effective therapies in this rare disease.
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform, Bolstering Oncology Portfolio
OncoX BioPharma Inc., an affiliate of ABVC BioPharma, has acquired the Lycopenoid Lycogen® platform, a move that could generate significant revenue through a scalable royalty strategy and strengthen ABVC's position in botanical oncology innovation.